Facilitating the Implementation of Population-wide Genomic Screening (FOCUS)
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Caitlin Allen, PhD
- Numéro de téléphone: 614-554-5298
- E-mail: Caitlin.Allen@wfusm.edu
Lieux d'étude
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599
- University of North Carolina
-
Contact:
- Megan Roberts
- Numéro de téléphone: 919-962-2211
- E-mail: megan.roberts@unc.edu
-
Greensboro, North Carolina, États-Unis, 27401
- Moses Cone Hospital
-
Contact:
- Alison Sigmon
- Numéro de téléphone: 919-962-2211
- E-mail: alison.sigmon@conehealth.com
-
Winston-Salem, North Carolina, États-Unis, 27157
- Atrium Health Wake Forest Baptist
-
Contact:
- Lori Orlando
- Numéro de téléphone: 704-863-6000
- E-mail: Lori.Orlando@wfusm.edu
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, États-Unis, 18015
- St. Luke's University Hospital
-
Contact:
- Christopher Chapman
- Numéro de téléphone: 866-785-8537
- E-mail: Christopher.Chapman@sluhn.org
-
York, Pennsylvania, États-Unis, 17403
- WellSpan York Hospital
-
Contact:
- Anwar Chahal
- Numéro de téléphone: 717-851-2345
- E-mail: cchahal@wellspan.org
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Baylor College of Medicine
-
Contact:
- Kyler Godwin
- Numéro de téléphone: 713-798-4951
- E-mail: Kyler.Godwin@bcm.edu
-
Houston, Texas, États-Unis, 77030
- Memorial Hermann-Texas Medical Center
-
Contact:
- Farhaan Vahidy
- Numéro de téléphone: 713-704-4000
- E-mail: Farhaan.Vahidy@memorialhermann.org
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Operate an active or population genomic screening (PGS) program.
- Agree to utilize the FOCUS Toolkit throughout the trial and engage staff in its use and fidelity tracking.
- Ability to understand and willingness to sign a data use agreement and comply with study procedures for the entire length of the study.
- Ability to provide program-level data (Reach, Effectiveness, Adoption, Implementation, Maintenance) quarterly.
- Confirmation of implementing or sustaining stage, as determined by the investigator.
- Capacity to participate in stakeholder surveys and interviews at study conclusion.
- Ability to read and understand the English language.
Exclusion Criteria:
- They lack infrastructure to collect and share required data.
- They cannot commit to toolkit use or quarterly reporting.
- They are unable to comply with study timelines
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Nombre de groupes / cohortes
Cohortes et interventions
Groupe / CohorteGroupe / Cohorte |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
FOCUS Toolkit
|
The FOCUS toolkit is a multicomponent implementation guide on improving the implementation of population-wide genomic screening programs across diverse healthcare settings.
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of People Participating in PGS Program
Délai: Month 4
|
Reach is measured as the total number of people who have consented to participate in the population-based genomic screening (PGS) program.
Data will be collected from PGS program data collection form
|
Month 4
|
|
Number of People Participating in PGS Program
Délai: Month 10
|
Reach is measured as the total number of people who have consented to participate in the population-based genomic screening (PGS) program.
Data will be collected from PGS program data collection form
|
Month 10
|
|
Number of People Participating in PGS Program
Délai: Month 16
|
Reach is measured as the total number of people who have consented to participate in the population-based genomic screening (PGS) program.
Data will be collected from PGS program data collection form
|
Month 16
|
|
Proportion of Eligible Individuals Tested
Délai: Month 4
|
Effectiveness is measured as the proportion of eligible individuals tested compared to those consented
|
Month 4
|
|
Proportion of Eligible Individuals Tested
Délai: Month 10
|
Effectiveness is measured as the proportion of eligible individuals tested compared to those consented
|
Month 10
|
|
Proportion of Eligible Individuals Tested
Délai: Month 16
|
Effectiveness is measured as the proportion of eligible individuals tested compared to those consented
|
Month 16
|
|
Proportion of Positive Genomic Screening Results
Délai: Month 4
|
Number of individuals with positive results after genomic screening
|
Month 4
|
|
Proportion of Positive Genomic Screening Results
Délai: Month 10
|
Number of individuals with positive results after genomic screening
|
Month 10
|
|
Proportion of Positive Genomic Screening Results
Délai: Month 16
|
Number of individuals with positive results after genomic screening
|
Month 16
|
|
Proportion of Negative Genomic Screening Results
Délai: Month 4
|
Number of individuals with negative results after genomic screening
|
Month 4
|
|
Proportion of Negative Genomic Screening Results
Délai: Month 10
|
Number of individuals with negative results after genomic screening
|
Month 10
|
|
Proportion of Negative Genomic Screening Results
Délai: Month 16
|
Number of individuals with negative results after genomic screening
|
Month 16
|
|
Proportion of VUS Genomic Screening Results
Délai: Month 4
|
Number of individuals with variant of uncertain significance (VUS) after genomic screening
|
Month 4
|
|
Proportion of VUS Genomic Screening Results
Délai: Month 10
|
Number of individuals with variant of uncertain significance (VUS) after genomic screening
|
Month 10
|
|
Proportion of VUS Genomic Screening Results
Délai: Month 16
|
Number of individuals with variant of uncertain significance (VUS) after genomic screening
|
Month 16
|
|
Number of Sites Participating in PGS
Délai: Month 19
|
Adoption is defined as the uptake of population-based genomic screening (PGS) at each site, measured by the number of sites participating in PGS relative to those eligible.
Measured through stakeholder surveys
|
Month 19
|
|
Acceptability of Intervention Measure (AIM)
Délai: Month 19
|
Implementation will be assessed using the Acceptability of Intervention Measure survey includes 4 items with the total score range 4-20.
Higher scores indicate higher level of acceptability.
|
Month 19
|
|
Intervention Appropriateness Measure (IAM)
Délai: Month 19
|
Implementation will be assessed using the Intervention Appropriateness Measure survey includes 4 items with a total score range 4-20.
Higher scores indicate higher level of appropriateness.
|
Month 19
|
|
Feasibility of Intervention Measure (FIM)
Délai: Month 19
|
Implementation will be assessed using the Feasibility of Intervention Measure survey includes 4 items with a total score range 4-20.
Higher scores indicate higher level of feasibility.
|
Month 19
|
|
Number of Individuals that Completed High-Risk Management
Délai: Month 19
|
Maintenance will be assessed by the number of individuals with positive results that completed high-risk management
|
Month 19
|
|
Program Sustainability Assessment
Délai: Month 19
|
Maintenance will be assessed by using the Program Sustainability Assessment survey has 40 items with a total score range of 40-280.
Higher scores indicate greater sustainability capacity.
|
Month 19
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: Caitlin Allen, PhD, Atrium Health Wake Forest Baptist
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- IRB00143953
- R01HG013851-03 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .